Filing Flows › CervoMed (CRVO) › Q3 2025 › vs Q3 2024
CervoMed (CRVO) Q3 2025 vs Q3 2024 (year over year)
CervoMed's revenue fell $1.6M (-83%) from $1.9M in Q3 2024 to $323K in Q3 2025.
CervoMed, Q3 2025: revenue $323K (-83% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart draws each line against Q3 2024, the increases inside each band.
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $323K | $1.9M | −$1.6M | -83% |
| Other income, net | $318K | $643K | −$325K | -51% |
| Net loss | $7.7M | $4.8M | $3.0M | +63% |
| Costs & expenses | $8.4M | $7.3M | $1.0M | +14% |
| Operating costs | $8.4M | $7.3M | $1.0M | +14% |
| Research & development | $6.0M | $5.1M | $915K | +18% |
| General & admin | $2.3M | $2.2M | $115K | +5% |
| Operating cash sources | $7.7M | $4.8M | $3.0M | +63% |
| Share-based compensation | $292K | $271K | $21K | +8% |
| Working capital & other | $970K | −$372K | $1.3M | — |
| Cash used in operations | $6.5M | $4.9M | $1.6M | +33% |
| Net loss absorbed | $7.7M | $4.8M | $3.0M | +63% |
Questions
How much did CervoMed's revenue grow year over year in Q3 2025?
CervoMed's revenue fell $1.6M (-83%) from $1.9M in Q3 2024 to $323K in Q3 2025.